TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7746027
Drug: Limptar tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limptar tablets (1 tablet containing 215.5 mg quinine and 167.2 mg theophylline)
Study: 7746027
Drug: Limptar N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limptar N tablets (1 tablet containing 165.75 mg quinine)
Study: 7746027
Drug: Chininum dihydrochloricum
Normalized name: Ancylostoma caninum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chininum dihydrochloricum Buchler solution for injection (infusion of 163.3 mg quinine)
Study: 7746027
Drug: Euphyllin 0.48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin 0.48 (short infusion of 168.6 mg theophylline)
Study: 28957960
Drug: Latanoprost/dorzolamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost/dorzolamide combination
Study: 28957960
Drug: Dorzolamide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide monotherapy
Study: 20860592
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with low-level laser therapy
Study: 20860592
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment alone (Control)
Study: 9351762
Drug: Control pamphlet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control pamphlet on daily activities during pregnancy
Study: 8458315
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy supplement (3.31 MJ daily) for 3 months
Study: 8458315
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy supplement
Study: 26572887
Drug: CT scanogram
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT scanogram with 10% of the standard dose of ionizing radiation
Study: 26572887
Drug: CT scanogram
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT scanogram with 90% of the standard dose of ionizing radiation
Study: 26572887
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of native and repaired femurs using both doses
Study: 16270700
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (Duraphat) treatment applied twice a year at six-month intervals in school settings among 854 adolescents.
Study: 2878490
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump (CSII)
Study: 27126957
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group consumed fermented milk with Bifidobacterium lactis HN019 (80 mL daily, 2.72 × 10^10 CFU) for 45 days
Study: 22520791
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of blood pressure and self-titration of antihypertensive medication
Study: 11926889
Drug: Pramipexole, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42)
Study: 11926889
Drug: Carbidopa/levodopa, 25/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40)
Study: 7753739
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and heparin (adjunctive drugs)
Study: 7753739
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers and angiotensin-converting enzyme inhibitors
Study: 8018458
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg four times daily
Study: 7415650
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units of subcutaneous heparin twice a day for a fortnight
Study: 29615077
Drug: SGI-110 (guadecitabine)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGI-110 (guadecitabine) combined with gemcitabine and cisplatin (GC) chemotherapy
Study: 29615077
Drug: GC chemotherapy
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC chemotherapy (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15)
Study: 22686495
Drug: Intranasal oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxycodone (0, 14 & 28 mg)
Study: 20556471
Drug: 3‐monthly laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐monthly laser treatments with a StarLux 1,540‐nm fractional handpiece
Study: 18793361
Drug: Chemo-mechanical root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-mechanical root canal preparation
Study: 12766099
Drug: Oolong tea
Normalized name: oolong tea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oolong tea (1,500 ml) for 30 days
Study: 8930172
Drug: Sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroacetate (DCA) 30 mg/kg
Study: 8930172
Drug: Sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroacetate (DCA) 100 mg/kg
Study: 8930172
Drug: Sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroacetate (DCA) 15-50 mg/kg (second infusions)
Study: 6423317
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate aerosol (1 mg/actuation)
Study: 6423317
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate via Spinhaler (20 mg)
Study: 30282077
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (SH) treatment
Study: 29590544
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of therapy (combined regimens)
Study: 29590544
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of therapy (combined regimens)
Study: 1449019
Drug: Urso plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urso plus colchicine (1 mg/day)
Study: 1449019
Drug: Urso alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urso alone (10-12 mg/kg) for 12 months
Study: 16326671
Drug: Landiolol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.25 to 0.5 mg.kg(‐1))
Study: 16326671
Drug: Esmolol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1.0 mg.kg(‐1))
Study: 16326671
Drug: Landiolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.5 mg.kg(‐1))
Study: 12432320
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CON) with tracheostomy performed on PBD 14 if necessary
Study: 10521736
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 mg every 4‐6 hours)
Study: 8890875
Drug: Pharmaceutical interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical interventions
Study: 1683333
Drug: Zotepine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (3 x 75 mg)
Study: 1683333
Drug: Haloperidol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3 x 4 mg)
Study: 27794080
Drug: Oxygen at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen at 2 L/min
Study: 27794080
Drug: Air at
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air at 2 L/min
Study: 15827910
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) and medication therapy (MT) for the first 6 weeks, followed by MT only for the second 6 weeks.
Study: 15827910
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) and medication therapy (MT) for the second 6 weeks after receiving only MT for the first 6 weeks.
Study: 12350390
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) as adjunctive therapy, initiated at 0.5-1 mg/kg, titrated to a maximum of 12 mg/kg over a mean treatment period of 15.8 months (range 3-98 months).
Study: 12350390
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) as adjunctive therapy.
Study: 8952810
Drug: Indapamide 1.5
Normalized name: indapamide 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.5 mg sustained-release form
Study: 8952810
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg immediate-release form
Study: 1935254
Drug: 2 percent
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GEL [The Keeps ETHANOL 62 percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 percent topical minoxidil
Study: 25025854
Drug: Biphasic calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic calcium sulfate (CS) in combination with gamma‐radiated human mineralized allograft
Study: 18343262
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3-12 mg)
Study: 18343262
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3, 6, 9, 12, 15 mg/d)
Study: 12734745
Drug: Amlodipine suspension
Normalized name: amlodipine Oral Suspension
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine suspension
Study: 12734745
Drug: Amlodipine tablets
Normalized name: Levamlodipine Tablets
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine tablets
Study: 8739863
Drug: Astemizole-D (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole-D (10 mg astemizole and 240 mg pseudoephedrine)
Study: 8739863
Drug: Brompheniramine-D (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine-D (12 mg brompheniramine and 50 mg phenylpropanolamine)
Study: 1911497
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine and 100 micrograms fentanyl
Study: 25609940
Drug: Glycopyrronium 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 50 μg once daily
Study: 21162825
Drug: Fasting capillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting capillary blood glucose cut-off value of 6.0 mmol/L for undiagnosed diabetes mellitus
Study: 21162825
Drug: Fasting capillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting capillary blood glucose cut-off value of 5.7 mmol/L for impaired fasting glucose (IFG)
Study: 21162825
Drug: Fasting capillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting capillary blood glucose cut-off value of 5.7 mmol/L for impaired glucose tolerance (IGT)
Study: 17764477
Drug: Conventional cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarettes (FTC tar 11 mg; CC1)
Study: 17764477
Drug: Conventional cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarettes (FTC tar 6 mg; CC2)
Study: 17764477
Drug: Cigarette switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette switch (FTC tar 1 mg; CC3)
Study: 15564721
Drug: Rituximab (anti-CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (anti-CD20 antibody), administered in up to 4 treatment cycles, possibly in combination with corticosteroid, cyclophosphamide, and/or methotrexate.
Study: 15564721
Drug: Rituximab (anti-CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (anti-CD20 antibody)
Study: 11953726
Drug: Cephalexin (80-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (80-100 mg/kg/day)
Study: 9876550
Drug: Metoprolol (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (generic preparation)
Study: 31678947
Drug: Exercise 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise 150 min/week + Liraglutide 3.0 mg/day
Study: 28143414
Drug: Toothbrushing plus
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothbrushing plus 0.12% chlorhexidine gel
Study: 28143414
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution 0.12% without toothbrushing
Study: 18172769
Drug: Drug Court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Court with usual community‐based treatment (DC)
Study: 18172769
Drug: DC with
Normalized name: ADC with Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC with Multisystemic Therapy (DC/MST)
Study: 18172769
Drug: Family Court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Court with usual community‐based treatment (FC)
Study: 17926489
Drug: Complex treatment
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex treatment with monocinque and melatonin
Study: 17926489
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with monocinque
Study: 9684909
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (120 mg ZnSO4 after each dialysis session)
Study: 2670447
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of heparin (subcutaneously, twice daily) for 14 to 21 days
Study: 2670447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without anticoagulant prophylaxis
Study: 1158003
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution infiltration
Study: 3111166
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose intravenous infusion
Study: 21219504
Drug: Oral swab
Normalized name: Moi-Stir, oral swab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral swab test
Study: 7854376
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches (10 mg taken five times daily)
Study: 1941832
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) at a dosage of 0.15‐0.2 mg/kg/day (9 mg/day maximum)
Study: 19736051
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol and simethicone solution (2l) 16h before VCE
Study: 12090863
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Study: 11339515
Drug: Intramuscular meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meloxicam (15 mg)
Study: 11339515
Drug: Oral meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral meloxicam (15 mg)
Study: 2040038
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (120 mg i.v. repeated after 4 hours) + metoclopramide (0.5 mg/kg i.v. bolus over 30 min + 1 mg/kg continuous infusion over 24 h) + alprazolam (0.5 mg p.o.)
Study: 2040038
Drug: Conventional antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional antiemetic regimen (metoclopramide + alprazolam) without high-dose methylprednisolone
Study: 31964449
Drug: AMPH ER
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH ER TAB 20 mg swallowed (fasted)
Study: 31964449
Drug: AMPH ER
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH ER TAB 20 mg chewed (fed/fasted)
Study: 24915175
Drug: Saffron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (300 mg/d)
Study: 24915175
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg, 25 mg thrice a day)
Study: 23809501
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist initiation on cycle day 2
Study: 23809501
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist initiation on cycle day 6 (control)
Study: 19898206
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus with mycophenolate mofetil and steroids until day 91 (Tac‐s)
Study: 18085138
Drug: Integration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration treatment group (AMIE methods: acupuncture, massage, injection, and animal exercise therapies)
Study: 18085138
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (Bobath training therapy)
Study: 14967451
Drug: EGFR inhibitors
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR inhibitors (monoclonal antibodies and small molecular weight compounds)
Study: 14967451
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with EGFR inhibitors
Study: 12588463
Drug: Glucagon (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (4.8 microg kg(‐1) bolus followed by 9.6 microg kg(‐1) h(‐1) infusion)
Study: 10948696
Drug: Desmopressin (0.396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.396 microgram administered intravenously as a bolus injection)
Study: 29185878
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy (PST) for 6 weeks
Study: 27004462
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination (NC)
Study: 30471555
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (noNC)
Study: 20439345
Drug: Liposomal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal cisplatin (200 mg/m²) and paclitaxel (135 mg/m²)
Study: 20439345
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m²) and paclitaxel (135 mg/m²)
Study: 23932956
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy by mothers
Study: 11893434
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy by trained professionals
Study: 9689902
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D administration in addition to Rifampicin, Isoniazid and Streptomycin (Group B)
Study: 4214889
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative irradiation therapy
Study: 12730150
Drug: nCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP treatment
Study: 17296461
Drug: Tramadol 37.5-mg/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 37.5-mg/acetaminophen 325-mg combination tablets (tramadol/APAP)
Study: 14521597
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg alternate daily
Study: 14521597
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg day-1
Study: 14521597
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg day-1
Study: 2442543
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg b.i.d. on a low sodium diet (50 mmol sodium/24 h)
Study: 2442543
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg b.i.d. on a liberal sodium diet (200 mmol sodium/24 h)
Study: 2442543
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg b.i.d. on both diets
Study: 31420190
Drug: PCOS pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PCOS pharmaceutical care service (verbal and written educational materials focusing on diet and exercise)
Study: 24087999
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (60 mg/day for 8 weeks)
Study: 16111790
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of live attenuated oral monovalent G1 human rotavirus vaccine
Study: 16111790
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of live attenuated oral monovalent G1 human rotavirus vaccine
Study: 16111790
Drug: Routine childhood
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine childhood vaccines
Study: 16111790
Drug: Both dosages
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosages of HRV vaccine